NCT04997096Recruiting
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Source: ClinicalTrials.gov · Last updated 19 Feb 2026
Brief summary (registry, in English)
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 4 Aug 2021
- Start date
- 2 Apr 2022
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT04997096
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 2 Apr 2022 to the primary completion date, 1 Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)
Other illness
- Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
- Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
- Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
Who the study is looking for
- Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
- Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
- ≥18 years, children under the age of 18 will be excluded due to rarity of disease
- Physician's clearance to participate in moderate-vigorous intensity exercise
- Able to read, write, and understand English
- Ability to understand and the willingness to sign an informed consent document
- Willing to undergo two venous blood draws for the study
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.